Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic : Two challenging and informative clinical cases
© 2020 Wiley Periodicals, Inc..
BACKGROUND AND METHODS: There is an added level of complexity in the management of head and neck cancer patients with underlying immunosuppressive disorders during the COVID-19 pandemic. Head and neck oncologists are tasked with balancing the dual risks of cancer progression in the setting of impaired tumor immunity and increased susceptibility to life-threatening complications from exposure to viral infection for patients and providers. Through two cases of immunocompromised patients with newly diagnosed head and neck malignancies, we aim to provide guidance to clinicians struggling with how to best counsel and manage this unique subset of patients under these difficult circumstances.
RESULTS: After careful consideration of the options, we took different approaches in the care of these two patients.
CONCLUSIONS: Ultimately, there is no uniform set of rules to apply to this heterogeneous group of immunocompromised patients. We provide some general principles to help guide patient management during the current pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Head & neck - 42(2020), 6 vom: 10. Juni, Seite 1131-1136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Civantos, Alyssa M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Airway |
|---|
| Anmerkungen: |
Date Completed 10.06.2020 Date Revised 18.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hed.26165 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308828976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308828976 | ||
| 003 | DE-627 | ||
| 005 | 20231225132559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hed.26165 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308828976 | ||
| 035 | |a (NLM)32298006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Civantos, Alyssa M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic |b Two challenging and informative clinical cases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals, Inc. | ||
| 520 | |a BACKGROUND AND METHODS: There is an added level of complexity in the management of head and neck cancer patients with underlying immunosuppressive disorders during the COVID-19 pandemic. Head and neck oncologists are tasked with balancing the dual risks of cancer progression in the setting of impaired tumor immunity and increased susceptibility to life-threatening complications from exposure to viral infection for patients and providers. Through two cases of immunocompromised patients with newly diagnosed head and neck malignancies, we aim to provide guidance to clinicians struggling with how to best counsel and manage this unique subset of patients under these difficult circumstances | ||
| 520 | |a RESULTS: After careful consideration of the options, we took different approaches in the care of these two patients | ||
| 520 | |a CONCLUSIONS: Ultimately, there is no uniform set of rules to apply to this heterogeneous group of immunocompromised patients. We provide some general principles to help guide patient management during the current pandemic | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a airway | |
| 650 | 4 | |a head and neck cancer | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a risk management | |
| 700 | 1 | |a Carey, Ryan M |e verfasserin |4 aut | |
| 700 | 1 | |a Lichtenstein, Gary R |e verfasserin |4 aut | |
| 700 | 1 | |a Lukens, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Roger B |e verfasserin |4 aut | |
| 700 | 1 | |a Rassekh, Christopher H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Head & neck |d 1996 |g 42(2020), 6 vom: 10. Juni, Seite 1131-1136 |w (DE-627)NLM012791806 |x 1097-0347 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2020 |g number:6 |g day:10 |g month:06 |g pages:1131-1136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hed.26165 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2020 |e 6 |b 10 |c 06 |h 1131-1136 | ||